Stock In Radar | Biocon in focus as USFDA classifies its Malaysia facility as VAI after Sept 15–27, 2024 inspection. "Positive USFDA update, but can Biocon break out after years of consolidation? Debt remains a key concern," says Nikunj Dalmia. Listen in! #market #stocksonradar #StocksInNews | Biocon Biologics | ET NOW | Facebook

🔬 Biocon shares jumped after reports said the company is exploring a merger of its biosimilars arm, Biocon Biologics, with the parent firm. The move aims to unlock value and streamline operations. 💊 Biocon is a leading biopharma company focused on biologics, biosimilars, and research services, working to make advanced treatments more accessible worldwide. 🤔 Could this merger reshape Biocon’s growth story in the global biopharma space? Follow @portal.tradebrains Follow @portal.tradebrains #bio

#NiftyPharma was the top sectoral gainer this week! Here's what our research team has to say. Disc: https://bit.ly/KSLResearchDisclaimer #KotakSecurities #WeeklyWaves #Pharma #Cipla #SunPharma #Biocon #DrReddy #GlandPharma #Lupin #DivisLaboratories #TorrentPharma | Kotak Securities | Facebook